CAR T cell therapy for FRa-positive cancers
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment called MOv19-BBz CAR T cells, which are specially designed immune cells that target a protein called FRa found on some cancer cells. It's for people with advanced lung cancer that has spread to the lining of the lung (malignant pleural effusion) and who have already tried at least one standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a protein called FRa on at least 10% of its cells, which can be checked on a sample from a past biopsy or surgery.
- You must have advanced lung adenocarcinoma that has spread to the lining of the lung (malignant pleural effusion) and it must be getting worse despite prior treatment.
- You need to be in fairly good health, with an ECOG performance status of 0 or 1, meaning you can do most daily activities without help.
- Your heart and lungs must work well enough, with a left ventricle pumping ability of 40% or more, no severe shortness of breath, and oxygen levels above 92% on room air.
- You cannot have other active cancers, uncontrolled infections, or autoimmune diseases that need high-dose steroids or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
This trial tests a new type of immunotherapy where your own immune cells are collected, modified to recognize and attack cancer cells, and then returned to your body. It may be an option for people with B-cell cancers that have not responded to other treatments.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
Hear when a new Recurrent Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.